Cargando…

Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment

A high recurrence rate of non-Hodgkin's lymphoma (NHL) following chimeric antigen receptor T (CAR T) cell treatment remains a bottleneck, and immunosuppressive tumor microenvironment (TME) compromising CAR T cell efficacy in NHL is the primary cause of relapse. Accordingly, modifying the struct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Yingqi, Liao, Peiyun, Wang, Hao, Chen, Jianyu, Hu, Yuxing, Hu, Rong, Zhang, Honghao, Li, Zhongwei, Cao, Manxiong, Yang, Yulu, Li, Meifang, Xie, Xiaoling, Li, Yuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539696/ https://www.ncbi.nlm.nih.gov/pubmed/37781520 http://dx.doi.org/10.7150/ijbs.86632

Ejemplares similares

Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia
por: Wang, Hao, et al.
Publicado: (2023)

Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
por: Chen, Jianyu, et al.
Publicado: (2021)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

Polyfunctional CD4(+) T Cells As Targets for Tuberculosis Vaccination
por: Lewinsohn, Deborah A., et al.
Publicado: (2017)

Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia
por: Chang, Ning, et al.
Publicado: (2023)

Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases
por: Dou, Manman, et al.
Publicado: (2020)

Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker
por: Qiu, Yingqi, et al.
Publicado: (2022)

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
por: Wang, Qianqian, et al.
Publicado: (2023)

Generation and utilization of polyfunctional anti-tumor CD4+ T cells
por: Zhou, Gang, et al.
Publicado: (2015)

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
por: Shu, Runzhe, et al.
Publicado: (2021)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells
por: Boudousquie, Caroline, et al.
Publicado: (2017)

Depletion of polyfunctional CD26(high)CD8(+) T cells repertoire in chronic lymphocytic leukemia
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL
por: Zhang, Qiong, et al.
Publicado: (2019)

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
por: Xue, Qiong, et al.
Publicado: (2017)

IL7 signaling confers polyfunctionality to antitumor CD4+ T cells
por: Zhou, Gang, et al.
Publicado: (2014)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2017)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals
por: Li, Yang, et al.
Publicado: (2022)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8(+) T cells for adoptive immunotherapy
por: Mousset, Charlotte M., et al.
Publicado: (2018)

CD4(+) T cells support polyfunctionality of cytotoxic CD8(+) T cells with memory potential in immunological control of tumor
por: Imai, Naoko, et al.
Publicado: (2020)

Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a
por: Vitallé, Joana, et al.
Publicado: (2020)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity
por: Xie, Xiaoling, et al.
Publicado: (2018)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

CD47 on artificial structures
por: Schütz, Christian
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4g0qks9la9do850frj63cvkv8v